Receptor Tyrosine Kinase-Targeted Cancer Therapy

In the past two decades, several molecular targeted inhibitors have been developed and evaluated clinically to improve the survival of patients with cancer. Molecular targeted inhibitors inhibit the activities of pathogenic tyrosine kinases. Particularly, aberrant receptor tyrosine kinase (RTK) acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaoka, Toshimitsu, Kusumoto, Sojiro, Ando, Koichi, Ohba, Motoi, Ohmori, Tohru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274851/
https://www.ncbi.nlm.nih.gov/pubmed/30404198
http://dx.doi.org/10.3390/ijms19113491

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274851/
https://www.ncbi.nlm.nih.gov/pubmed/30404198
http://dx.doi.org/10.3390/ijms19113491

Ejemplares similares